Caribou Biosciences Inc (nasdaq:CRBU) Share Price

Company Profile

Business description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Contact
2929 7th Street
Suite 105
BerkeleyCA94710
USA
T: +1 510 982-6030
https://www.cariboubio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
147

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	20.50	-0.23%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,287.23	144.81	0.31%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	0.25	0.00%
NASDAQ	22,571.17	100.45	0.45%
Nikkei 225	45,045.81	257.62	-0.57%
NZX 50 Index	13,231.66	111.63	0.85%
S&P 500	6,652.43	20.47	0.31%
S&P/ASX 200	8,773.50	18.70	-0.21%
SSE Composite Index	3,820.09	11.57	-0.30%